Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Byooviz Generic Name & Formulations
Legal Class
Rx
General Description
Ranibizumab-nuna 10mg/mL (0.5mg); soln for oph intravitreal inj; preservative-free.
Pharmacological Class
Vascular endothelial growth factor (VEGF) inhibitor.
How Supplied
Single-dose vial—1
Manufacturer
Generic Availability
NO
Byooviz Indications
Indications
Neovascular (wet) age-related macular degeneration (AMD). Macular edema following retinal vein occlusion (RVO). Myopic choroidal neovascularization (mCNV).
Byooviz Dosage and Administration
Adult
Give by intravitreal inj. AMD: 0.5mg once a month (approx. 28 days); or 3 monthly doses followed by less frequent dosing (less effective); or 0.5mg every 3 months after 4 monthly doses (less effective). Monitor regularly. RVO: 0.5mg once a month (approx. 28 days). mCNV: 0.5mg once a month (approx. 28 days) for up to 3 months; may retreat if needed.
Children
Not established.
Byooviz Contraindications
Contraindications
Ocular or periocular infections.
Byooviz Boxed Warnings
Not Applicable
Byooviz Warnings/Precautions
Warnings/Precautions
Monitor intraocular pressure prior to and 30mins after inj. Monitor for perfusion of optic nerve head and for infection following the inj (endophthalmitis and retinal detachments possible). Pregnancy; may cause embryo-fetal toxicity. Nursing mothers.
Byooviz Pharmacokinetics
See Literature
Byooviz Interactions
Not Applicable
Byooviz Adverse Reactions
Adverse Reactions
Conjunctival hemorrhage, eye pain, vitreous floaters, increased intraocular pressure, intraocular inflammation; rare: arterial thromboembolic events.
Byooviz Clinical Trials
See Literature
Byooviz Note
Not Applicable
Byooviz Patient Counseling
See Literature
Images
